Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 15;28(3):030501.
doi: 10.11613/BM.2018.030501.

"Ultra-sensitive" cardiac troponins: Requirements for effective implementation in clinical practice

Affiliations
Review

"Ultra-sensitive" cardiac troponins: Requirements for effective implementation in clinical practice

Giuseppe Lippi et al. Biochem Med (Zagreb). .

Abstract

The measurement of cardiac troponins, either cardiac troponin I or T, has become the culprit of clinical decision making in patients with suspected acute coronary syndrome (ACS), especially in those with non-ST elevation myocardial infarction (NSTEMI). The leading analytical mainstays of cardiac troponin immunoassays include the limit of blank (LoB), limit of detection (LoD), functional sensitivity, the 99th percentile of a healthy reference population, along with the percentage of "ostensibly healthy" subjects displaying measurable values < 99th percentile. The latest generation of cardiac troponin immunoassays, conventionally defined as "high-sensitive" (HS), is characterized by a LoD over 100-fold lower compared to the first commercialized techniques and a percentage of measurable values consistently > 50% in the general healthy population. The very recent commercialization of methods with further improved analytical sensitivity (i.e., "ultra-sensitive" assays), which allow to measure cardiac troponin values in the vast majority of healthy subjects, is now challenging the diagnostic paradigm based on early rule-out of subjects with cardiac troponin values comprised between the 99th percentile and LoD. New diagnostic strategies, entailing assay-specific cut-offs, must hence be developed and validated in large multicenter studies. The aim of this article is to provide an update on commercially available HS and "ultra"-sensitive techniques for measuring cardiac troponins, along with possible implications of increasingly enhanced analytical sensitivity on diagnostic algorithms for evaluating patients with suspected ACS.

Keywords: acute coronary syndrome; cardiac troponin; diagnostics; myocardial infarction.

PubMed Disclaimer

Conflict of interest statement

Potential conflict of interest: None declared.

Figures

Figure 1
Figure 1
Percentage of measurable values of cardiac troponin in healthy population. HS-cTnT - high sensitive cardiac troponin T. HS-cTnI - high sensitive cardiac troponin I. LoD - limit of detection. 99th percentile - 99th percentile of a reference healthy population.
Figure 2
Figure 2
Development of cut-offs for diagnostic algorithms including different cardiac troponin immunoassays. CV10% - coefficient of variation value with ≤ 10% analytical imprecision (functional sensitivity). LoD - limit of detection. 99th percentile - 99th percentile of a reference healthy population.

Similar articles

Cited by

References

    1. Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016;4:256. 10.21037/atm.2016.06.33 - DOI - PMC - PubMed
    1. Lippi G, Cervellin G. Do we really need high-sensitivity troponin immunoassays in the emergency department? Maybe not. Clin Chem Lab Med. 2014;52:205–12. 10.1515/cclm-2013-0524 - DOI - PubMed
    1. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Circulation. 2012;126:2020–35. 10.1161/CIR.0b013e31826e1058 - DOI - PubMed
    1. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267–315. 10.1093/eurheartj/ehv320 - DOI - PubMed
    1. Alvin MD, Jaffe AS, Ziegelstein RC, Trost JC. Eliminating creatine kinase-myocardial band testing in suspected acute coronary syndrome: A value-based quality improvement. JAMA Intern Med. 2017;177:1508–12. 10.1001/jamainternmed.2017.3597 - DOI - PubMed